Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells

BACKGROUND: For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspase...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Jin, Wang, Xue, Qu, Jun, Mager, Donald E., Straubinger, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583190/
https://www.ncbi.nlm.nih.gov/pubmed/33097020
http://dx.doi.org/10.1186/s12885-020-07398-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583190/
https://www.ncbi.nlm.nih.gov/pubmed/33097020
http://dx.doi.org/10.1186/s12885-020-07398-9

Ejemplares similares